James Stocks

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

Francis X. McCormack, Yoshikazu Inoue, Joel Moss et al. · New England Journal of Medicine · 2011 · 1.1K citations · Full text

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

Kenneth R. Chapman, Jonathan Burdon, Eeva Piitulainen et al. · The Lancet · 2015 · 494 citations

Lung Density, Pulmonary Pharmacology, Placebo-controlled Trial +4

6-Minute Walk Work for Assessment of Functional Capacity in Patients With COPD

Rick Carter, David B. Holiday, Chiagozie Nwasuruba et al. · CHEST Journal · 2003 · 232 citations

Physical Activity, Kinesiology, Health Sciences +12

Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial

Lisa R. Young, Hye Seung Lee, Yoshikazu Inoue et al. · The Lancet Respiratory Medicine · 2013 · 194 citations · Full text

Circulating polymers in α₁-antitrypsin deficiency

Lu Tan, Jennifer A. Dickens, Dawn L. DeMeo et al. · European Respiratory Journal · 2014 · 86 citations · Full text